- Home
- ACI vs CORT Comparison
ACI vs CORT Comparison
Compare ACI & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACI
- CORT
- Stock Information
- Founded
- ACI 1860
- CORT 1998
- Country
- ACI United States
- CORT United States
- Employees
- ACI N/A
- CORT N/A
- Industry
- ACI Food Chains
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- ACI Consumer Staples
- CORT Health Care
- Exchange
- ACI Nasdaq
- CORT Nasdaq
- Market Cap
- ACI 9.8B
- CORT 8.8B
- IPO Year
- ACI 2020
- CORT N/A
- Fundamental
- Price
- ACI $19.21
- CORT $76.81
- Analyst Decision
- ACI Strong Buy
- CORT Strong Buy
- Analyst Count
- ACI 15
- CORT 4
- Target Price
- ACI $24.13
- CORT $139.00
- AVG Volume (30 Days)
- ACI 7.6M
- CORT 1.0M
- Earning Date
- ACI 10-14-2025
- CORT 10-29-2025
- Dividend Yield
- ACI 3.12%
- CORT N/A
- EPS Growth
- ACI N/A
- CORT N/A
- EPS
- ACI 1.69
- CORT 1.11
- Revenue
- ACI $81,370,600,000.00
- CORT $716,080,000.00
- Revenue This Year
- ACI $4.90
- CORT $30.77
- Revenue Next Year
- ACI $0.57
- CORT $37.75
- P/E Ratio
- ACI $11.35
- CORT $70.90
- Revenue Growth
- ACI 2.08
- CORT 25.71
- 52 Week Low
- ACI $16.70
- CORT $42.01
- 52 Week High
- ACI $23.20
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- ACI 64.67
- CORT 45.45
- Support Level
- ACI $16.85
- CORT $69.43
- Resistance Level
- ACI $19.50
- CORT $91.00
- Average True Range (ATR)
- ACI 0.46
- CORT 4.07
- MACD
- ACI 0.26
- CORT -1.83
- Stochastic Oscillator
- ACI 89.64
- CORT 34.21
About ACI Albertsons Companies Inc.
Albertsons is the second-largest supermarket operator in the United States with about 2,300 stores across a variety of banners. Around 80% of the firm's sales comes from nonperishable and fresh food, of which 26% comes from its portfolio of private brands. The company operates fuel centers at about 20% of its store locations and pharmacies at 75%. Albertsons went public in 2020 following years of ownership under private equity firm Cerberus Capital Management, which still owns about a fourth of the outstanding shares.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.